Diagnosis of anomalies based on hybrid features extraction in thyroid images.

Multimed Tools Appl

Department of Computer, Ferdows Branch, Islamic Azad University, Ferdows, Iran.

Published: July 2022

Diagnosing benign and malignant glands in thyroid ultrasound images is considered a challenging issue. Recently, deep learning techniques have significantly resulted in extracting features from medical images and classifying them. Convolutional neural networks ignore the hierarchical structure of entities within images and do not pay attention to spatial information as well as the need for a large number of training samples. Capsule networks consist of different hierarchical capsules equivalent to the same layers in the convolutional neural networks. We propose a feature extraction method for ultrasound images based on the capsule network. Then, we combine those deep features with conventional features such as Histogram of Oriented Gradients and Local Binary Pattern together to form a hybrid feature space. We increase the accuracy percentage of a support vector machine (SVM) by balancing and reducing the data dimensions of samples. Since the SVM provides different training kernels according to the sample distribution method, the extracted textural features were categorized using each of these kernels to obtain the result. The parameters of classification evaluation using the researcher-made model have outperformed the other methods in this field. Experimental results showed that the combination of HOG, LBP, and CapsNet methods outperformed the others, with 83.95% accuracy in the SVM with a linear kernel.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289652PMC
http://dx.doi.org/10.1007/s11042-022-13433-7DOI Listing

Publication Analysis

Top Keywords

ultrasound images
8
convolutional neural
8
neural networks
8
features
5
images
5
diagnosis anomalies
4
anomalies based
4
based hybrid
4
hybrid features
4
features extraction
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Yonsei University, Incheon, Incheon, Korea, Republic of (South).

Background: As amyloid-β (Aβ) aggregates are considered as the biomarkers and key factors in the pathology of Alzheimer's disease, there has been extensive investigation into Aβ-targeting compounds for the development of diagnostics and drug discovery related to the disorder. However, the polymorphic and heterogenous nature of Aβ aggregates impedes the structural understanding of their structure. Consequently it is a major challenge to develop new diagnostic and therapeutic development of AD and to study the mechanism of Aβ-targeting compounds.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

University of California San Francisco (UCSF), San Francisco, CA, USA; Northern California Institute for Research & Education (NCIRE), San Francisco, CA, USA; San Francisco Veterans Administration Medical Center (SFVAMC), San Francisco, CA, CA, USA.

The Alzheimer's Disease Neuroimaging Initiative (ADNI) has made many important contributions to the development of Alzheimer's Disease (AD) disease modifying treatments and diagnostic biomarkers. Since its funding in 2004 by the National Institutes of Aging, the goal of ADNI has been the validation of biomarkers for AD treatment trials. ADNI has enrolled over 2,400 participants in the USA and Canada for longitudinal clinical, cognitive, and biomarker studies.

View Article and Find Full Text PDF

Background: Alzheimer's and related disorders (ADRD) represent a range of neurodegenerative conditions characterized by abnormal protein deposits in the brain. Despite advances, there is a need for enhanced diagnostic and treatment approaches that acknowledge the diversity of ADRD. This project introduces the Alzheimer's and Related Disorders Multicenter Archive (ARMA), a collaborative platform with an advanced Electronic Data Capture (EDC) system linked to Electronic Medical Records (EMR) designed to refine ADRD diagnosis and natural history understanding, thus informing precision medicine.

View Article and Find Full Text PDF

In Japan, the regulatory authority approved the drug in September 2023, and on December 20, it became available for prescription country-wide under the health insurance system. However, there are strict patient, physician, and facility requirements for the prescription of Lecanemab, and various problems are anticipated in its future implementation and widespread use in society. Lecanemab is the first anti-Aβ antibody in Japan, and even dementia specialists do not have sufficient knowledge and experience in its introduction, evaluation of efficacy, and evaluation and handling of side effects.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.

Real-World data platforms for Alzheimer's Disease (AD) offer a unique opportunity to improve health equity through better understanding of health disparities and inclusivity in research, which is critical to translatability of research findings. AD research in the US and globally remains largely inaccessible to many individuals due to individual-level, study-level, investigator-level and larger systemic barriers. ALZ-NET, a US-based registry to evaluate longitudinal outcomes of patients being evaluated for or treated with novel FDA-approved AD therapy, and New IDEAS, an observational US-based longitudinal study of amyloid PET clinical utility, both offer opportunities for examining care, inclusivity, and disparities.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!